Patients with myasthenia gravis experience higher comorbidity rates and healthcare utilization compared to healthy controls, indicating a significant disease burden. Treatment patterns for ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue of voluntary muscles. Essentially, antibodies cause a breakdown in ...

Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from the ...

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness. There are around 60,000 to 120,000 ...

Vyvgart (efgartigimod alfa-fcab) is a prescription drug that’s used to treat myasthenia gravis (MG ... MG is a kind of autoimmune disease. If you have an autoimmune disease, antibodies in ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...